Plus: Estrogen-only therapy may lower dementia risk, endometriosis costs women a month's salary, and a market gap for women aged 65+.
Next Phase Femtech launched with €1.6 million from the EU’s Interreg Öresund-Kattegat-Skagerrak program, providing funding for market-ready menopause solutions. Femtech operators and researchers are observing new funding pathways and clinical insights in women's health. Willow expanded its Hospital Partnership Program to Providence Saint John’s Health Center, donating five months’ worth of resources to support new families. Research suggests an association between oestrogen-only menopausal hormone therapy and fewer Alzheimer’s-related changes, informing future clinician strategies. Five takes inside, plus a quick-hits roundup.
VIA FemTech Insider
Next Phase Femtech launched with €1.6 million from the EU’s Interreg Öresund-Kattegat-Skagerrak program. The Research Unit at Zealand University leads the three-year initiative. Next Phase Femtech selected three market-ready menopause solutions, including Hormoner på Arbejde, MeWe&You Health, and Minimal. This funding supports new menopause solutions entering the market.
Read the full story →
— The Luteal Editorial Team
VIA FemTech Insider
Willow launched its Hospital Partnership Program at Providence Saint John’s Health Center, donating five months’ worth of resources, including Willow Breastfeeding Care Kits. This program provides postpartum resources and support to families giving birth. Willow also teamed up with Palomar Hospital through this partnership. Femtech operators can observe strategies for hospital collaboration and resource provision in maternal health.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Women using oestrogen-only menopausal hormone therapy had a 35% lower chance of showing biological signs of Alzheimer's disease than non-users, according to a study examining medical records from 21,462 women. The observational study also found a 39% lower risk of receiving a clinical dementia diagnosis for hormone therapy users. Researchers noted the findings do not demonstrate hormone therapy prevents dementia. This research suggests a potential association between oestrogen-only therapy and reduced Alzheimer's-related changes, informing future research for femtech operators and clinicians focusing on menopausal health.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Women with endometriosis lose an average of €1,757 in income each year, roughly equal to one month’s average salary in Hungary, according to a large-scale study in Central and Eastern Europe. This research analyzed data from 566 women with endometriosis, finding they lost 12.7 working hours over four weeks and 42% had poor work ability. Fifty-four percent of respondents stated their employer had little or no knowledge of the condition, which affects 10% of women of reproductive age worldwide. This highlights a critical need for solutions addressing workplace impact and employer education for femtech operators and clinicians.
Read the full story →
— The Luteal Editorial Team
VIA FutureFemHealth
Globally, 664 million women aged 60+ comprise over half of the 60+ population and 62% of those aged 80+. This demographic will grow to 1.13 billion by 2050, yet company creation for women aged 60+ lags despite the growth of menopause as a health category. Herself Health, a primary care company for women aged 65+, raised $7 million in seed funding and $26 million in Series A funding in 2023. Femtech operators and investors should note the underserved market for women living 30-40 years post-menopause, whose health priorities broaden to include bone, muscle, cardiovascular, and cognitive health.
Read the full story →
— The Luteal Editorial Team